Company intelligence / Profile preview
Merck KGaA
Darmstadt, Germanymerckgroup.com ↗
- Ownership
- Private
- Employees
- ~60334
- Development stage
- Commercial
01
Overview
Merck KGaA has a diverse pipeline with focus on oncology, including DNA Damage Response inhibitors and Antibody-Drug Conjugates. Their ATR inhibitor tuvusertib is in Phase II, PARP1 inhibitor M9466 in Phase Ib, anti-CEACAM5 ADC M9140 in Phase Ib for colorectal cancer, and anti-GD2 ADC M3554 entering first-in-human studies.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculesAntibody-Drug Conjugates (ADCs)DNA Damage Response (DDR) inhibitors
- Industry
- Pharma
02
Drug pipeline
76 assets75 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Merck KGaA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Merck KGaA.